The FY2023 (Dec) proxy of Lyell Immunopharma names 21 peer companies for pay. Among Lyell Immunopharma and these peers, CEO pay was 10th highest of 12 and total shareholder return was 11th highest of 12.
10th highest of 12in Lyell Immunopharma and its pay peers, FY2023 (Dec) by CEO pay:
$1.2M$19.8M
11th highest of 12in Lyell Immunopharma and its pay peers, FY2023 (Dec) by total shareholder return:
$4$208
Pay peer group, FY2023 (Dec) proxy
| Relay Therapeutics | ||
| Allogene Therapeutics | ||
| CRISPR Therapeutics AG | ||
| Intellia Therapeutics | ||
| Revolution Medicines | ||
| Arcus Biosciences | ||
| Beam Therapeutics | ||
| Iovance Biotherapeutics | ||
| Fate Therapeutics | ||
| Editas Medicine | ||
| ImmunityBio | ||
| Atara Biotherapeutics | Not disclosed | Not disclosed |
| Century Therapeutics | Not disclosed | Not disclosed |
| Erasca | Not disclosed | Not disclosed |
| IGM Biosciences | Not disclosed | Not disclosed |
| Instil Bio | Not disclosed | Not disclosed |
| NGM Biopharmaceuticals | Not disclosed | Not disclosed |
| Prometheus Biosciences | Not disclosed | Not disclosed |
| Sana Biotechnology | Not disclosed | Not disclosed |
| Turning Point Therapeutics | Not disclosed | Not disclosed |
| Zentalis Pharmaceuticals | Not disclosed | Not disclosed |
21 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.